Alon Meir

Alon Meir has a diverse work experience in the field of biotechnology and research. Alon started their career at Alomone in 2001, where they served as the CSO and R&D manager. During their time there, they were involved in all aspects of research reagents production and commercialization. Alon also led discovery projects in collaboration with pharmaceutical and other companies. In 2008, they co-founded Alomone Preclinical, where they continue to work till date. In 2016, they joined Seevix Material Sciences as the VP of Research and Development, and later became the Chief Scientist. Additionally, they worked as a Senior Lab Manager at NIBN in 2016, in the lab of Prof. Varda Shoshan-Barmatz, focusing on mitochondria, metabolism, cancer therapy, and VDAC.

Alon Meir earned a Ph.D in Physiology from The Hebrew University of Jerusalem, which they pursued from 1990 to 1996. Following this, in 2016, they briefly attended The Technion to study Medicinal Cannabis, although it is unclear if they completed a degree in this field. Additionally, from 1996 to 2001, Meir pursued a Postdoc at University College London (UCL) with a focus on Calcium channels.